Robin L. Carson
Impact in
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments
- Oncology top 5%
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
Papers in
- Hematology 48
- Multiple Myeloma Research and Treatments 45
- Chronic Myeloid Leukemia Treatments 4
- Oncology 20
- Peptidase Inhibition and Analysis 11
- Cancer Treatment and Pharmacology 7
- Co-authors
- María‐Victoria Mateos (6 shared papers)Andrew G Spencer (4 shared papers)Xiang Qin (3 shared papers)Pieter Sonneveld (5 shared papers)Ivan Špıčka (2 shared papers)Meral Beksac (4 shared papers)Katja Christina Weisel (3 shared papers)Jodi Carey (3 shared papers)
- Journals
- Blood (17 papers)HemaSphere (4 papers)Annals of Hematology (4 papers)New England Journal of Medicine (3 papers)The Lancet Oncology (2 papers)
- Partner nations
- United StatesNetherlandsSpain
In The Last Decade
Robin L. Carson
47 papers receiving 2.3k citations
Robin L. Carson's Hit Papers
Peers
Comparison fields: 5 of 59
- Hematology 1.9k
- Oncology 980
- Genetics 228
- Molecular Biology 965
- Physiology 51
Countries citing papers authored by Robin L. Carson
This map shows the geographic impact of Robin L. Carson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin L. Carson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin L. Carson more than expected).
Fields of papers citing papers by Robin L. Carson
This network shows the impact of papers produced by Robin L. Carson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin L. Carson. The network helps show where Robin L. Carson may publish in the future.
Co-authors
The 25 scholars most cited alongside Robin L. Carson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma Hit paper breakdown → | 2017 | 798 |
| 2 | Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma Hit paper breakdown → | 2023 | 348 |
| 3 | Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial Hit paper breakdown → | 2021 | 262 |
| 4 | 2018 | 187 | |
| 5 | 2022 | 92 | |
| 6 | 2023 | 92 | |
| 7 | 2024 | 51 | |
| 8 | 2020 | 48 | |
| 9 | 2020 | 38 | |
| 10 | 2024 | 33 | |
| 11 | 2022 | 32 | |
| 12 | 2024 | 30 | |
| 13 | 2023 | 25 | |
| 14 | 2022 | 18 | |
| 15 | 2021 | 17 | |
| 16 | 2017 | 15 | |
| 17 | 2022 | 14 | |
| 18 | 2020 | 14 | |
| 19 | 2020 | 14 | |
| 20 | 2022 | 13 |
About Robin L. Carson
Robin L. Carson is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Organic Chemistry, having authored 50 papers that have together received 2.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (45 papers), Peptidase Inhibition and Analysis (11 papers), Protein Degradation and Inhibitors (9 papers), Cancer Treatment and Pharmacology (7 papers), Cancer therapeutics and mechanisms (5 papers), Chronic Myeloid Leukemia Treatments (4 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Hematology (1.9k citations), Oncology (980 citations), Genetics (228 citations), Molecular Biology (965 citations) and Physiology (51 citations). Robin L. Carson has collaborated with scholars based in United States, Netherlands and Spain. Frequent co-authors include María‐Victoria Mateos, Andrew G Spencer, Xiang Qin, Pieter Sonneveld, Ivan Špıčka, Meral Beksac, Katja Christina Weisel, Jodi Carey, Tamás Masszi and Tomer Martin Mark. Their work appears in journals such as Blood, HemaSphere, Annals of Hematology, New England Journal of Medicine and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.